Get the Stockscreener App
1.80
5.26%
-0.10
NanoViricides Inc stock is traded at $1.80, with a volume of 175.03K.
It is down -5.26% in the last 24 hours and up +26.76% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.90
Open:
$1.85
24h Volume:
175.03K
Relative Volume:
0.82
Market Cap:
$28.69M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-2.5714
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
+8.43%
1M Performance:
+26.76%
6M Performance:
+45.16%
1Y Performance:
+20.81%
1-Day Range:
$1.78
$1.92
1-Week Range:
$1.65
$2.2299
52-Week Range:
$0.94
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.785 | 33.12M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.35 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
644.27 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.07 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
845.38 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.94 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - Bergen Record
How to build a dashboard for NanoViricides Inc. stockJuly 2025 News Drivers & AI Forecast Swing Trade Picks - newser.com
NanoViricides’ NV-387 shows broad antiviral potential, says Zacks - Proactive financial news
Has NanoViricides Inc. found a price floorJuly 2025 Trends & Fast Gaining Stock Strategy Reports - newser.com
Is NanoViricides Inc. stock a defensive play amid uncertaintyMarket Growth Summary & Real-Time Volume Analysis - newser.com
How NanoViricides Inc. stock trades after earningsEarnings Risk Summary & Detailed Earnings Play Alerts - newser.com
Why NanoViricides Inc. stock is upgraded to buyEarnings Trend Report & Safe Capital Allocation Plans - newser.com
Can NanoViricides Inc. stock hit consensus price targetsShort Setup & Long Hold Capital Preservation Plans - newser.com
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - Springfield News-Leader
Combining machine learning predictions for NanoViricides Inc.CEO Change & Verified Technical Signals - newser.com
Why NanoViricides Inc. stock appeals to dividend seekersWeekly Risk Report & AI Powered Market Entry Strategies - newser.com
NanoViricides Sets 2025 Annual Shareholders Meeting Amid Clinical Development Push - citybuzz -
How NanoViricides Inc. (NV3P) stock trades after rate cutsTrade Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Can NanoViricides Inc. (NV3P) stock ride next bull market cycleCEO Change & Weekly Watchlist for Hot Stocks - newser.com
Will NanoViricides Inc. stock benefit from sector leadershipJuly 2025 WrapUp & Expert-Curated Trade Recommendations - fcp.pa.gov.br
Why NanoViricides Inc. stock is a must watch in 2025Portfolio Return Summary & Real-Time Volume Analysis - fcp.pa.gov.br
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT - Lelezard
Will NanoViricides Inc. stock split attract more investors2025 Trade Ideas & Consistent Growth Equity Picks - newser.com
Is NanoViricides Inc. stock undervalued vs historical averages2025 Growth vs Value & AI Enhanced Trading Signals - newser.com
How to use Fibonacci retracement on NanoViricides Inc.2025 Dividend Review & Community Driven Trade Alerts - newser.com
Identifying reversal signals in NanoViricides Inc.July 2025 Highlights & Growth Oriented Trade Recommendations - newser.com
Using portfolio simulators with NanoViricides Inc. includedQuarterly Profit Review & High Accuracy Buy Signal Tips - newser.com
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - The Northwest Florida Daily News
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - Herald Times Reporter
NanoViricides to Present Antiviral Drug Pipeline at Spartan Capital Investor Conference - citybuzz -
NanoViricides (NYSE American: NNVC) to present 09:45 ET at Spartan Capital Conference 2025 - Stock Titan
NanoViricides to present at Spartan Capital Investor Conference 2025 in New York - Proactive financial news
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):